Up and Away, M&A

by

Mergers and acquisitions are positive for the CDMO industry, but there is a downside. Mergers and acquisitions (M&A) are a central feature of the contract development and manufacturing (CDMO) industry today. Several new deals are being announced every month, some of them quite substantial, and these deals are reshaping the industry. CDMOs are in great […]

Learn more

Sizeable South African Market Attracts, Challenges Pharma Industry Investment

by

South Africa’s pharmaceutical market, the largest and most developed in Sub-Saharan Africa, is expanding at a good clip, making it attractive to drug makers seeking a foothold in the broader African region. Those opportunities are challenged by such factors as intellectual property issues, regulatory inconsistency, remoteness from other global markets and relatively low per capital […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. ARMO BioSciences is a US private company that develops immunotherapies for the treatment of cancer, cardiovascular diseases, fibrosis and inflammation. It raised $67 million in […]

Learn more

Follow the Money to Medical Devices & Diagnostics
Spotlight on SetPoint Medical Corp.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. SetPoint Medical is a US private company that focuses on implantable neuromodulation devices to treat inflammatory diseases such as […]

Learn more

CDMOs Buttressed by Resilient Emerging Biopharma Sector

by

Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015 (see Figure 1, below). Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction […]

Learn more

CMOs Must Embrace Flexible Manufacturing

by

The need for flexibility in manufacturing arrangements and technologies has never been greater. New products are more technically challenging, produced in smaller volumes, and subject to great market uncertainty stemming from competing therapies and reimbursement risk. Contract development and manufacturing organizations (CDMOs) need to respond in both technical capabilities and business model flexibility to address […]

Learn more

Populating Your CRM with New Business Opportunities

by

Integrating the PharmSource Lead Sheet leads and contacts into your company’s customer relationship management (CRM) can be an important part of following up on the targeted new business opportunities you identify. Many companies use the Lead Sheet very efficiently by diligently tagging appropriate leads and importing selective data into their CRMs. This ensures that incoming data is relevant to […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on CymaBay Therapeutics

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. CymaBay Therapeutics, formerly known as Metabolex, develops drugs to treat diabetes and related metabolic disorders. It plans to raise $84.5 million in a secondary public […]

Learn more

Follow the Money to Medical Devices & Diagnostics
Spotlight on SEBACIA, Inc.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. SEBACIA, Inc. is a US private company that develops light-based therapies for the treatment of dermatological conditions. It raised […]

Learn more

Bio/Pharma Financing and Drug Approvals Bounce Back in 2017

by

The bio/pharma sector enjoyed a healthy first half of the year, as several key metrics rebounded strongly from a disappointing 2016. The sector raised $18.1 billion in the first six months of the year, more than double the figure seen for the same period last year, although 12% lower than the record amount recorded in […]

Learn more